What happened with PMI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Picard Medical, Inc. operates through its wholly owned subsidiary SynCardia, which makes an implanted artificial heart for patients with advanced heart failure awaiting a transplant. The SynCardia Total Artificial Heart replaces both ventricles and all four heart valves, while an external driver powers its pumping. Hospitals buy the implant kits, which generate most revenue. Some patients can leave hospital with a portable Freedom Driver, which provides a smaller stream of rental income.
Its customers are medical centers with heart-transplant and mechanical-circulatory-support programs, and most revenue comes from the United States. Hospitals pay Picard; Medicare and private insurers reimburse hospitals for treatment rather than paying Picard directly. Adequate reimbursement therefore matters to hospitals’ willingness to use the device. Revenue is concentrated among a few customers, with one accounting for a particularly large share, and orders generally carry no long-term volume commitment.
U.S. approval covers use while patients await transplantation, not permanent treatment in place of a transplant. Production is concentrated at SynCardia’s Tucson facility. The company also depends on Bimba and its distributor Heitek Automation for sole-source driver components, purchased without long-term supply agreements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Picard Medical’s results hinge on adoption by a small network of transplant centers and broader regulatory approvals, with Carmat and BiVACOR offering closer total-artificial-heart competition than Abbott.
Abbott competes with Picard for advanced-heart-failure programs considering devices to support blood circulation: Abbott’s HeartMate devices help the heart pump, while Picard sells total artificial hearts to medical centers with transplant and mechanical-support programs.
Abbott Laboratories earningsABT
Abbott's report will show demand for HeartMate circulatory-support devices at advanced-heart-failure programs, offering a demand signal for Picard Medical at the same kinds of medical centers.
Look at Abbott's HeartMate-related sales and what it says about that business. Resilient sales would show hospitals still buying circulatory-support devices, but HeartMate helps the heart pump; it is not Picard's total artificial heart, so this would not prove hospitals will buy Picard's product. Weaker results would point to a softer demand backdrop at shared medical centers, leaving Picard to prove through its own kit sales that doctors and hospitals will adopt a total artificial heart.
Fed Interest Rate Decision
Fed rate decisions influence the cost and availability of borrowing across the economy, which matters to Picard because it relies on debt or equity funding to support operations while its SynCardia artificial-heart business works toward sufficient revenue.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can make future borrowing more expensive or harder to obtain, potentially increasing what Picard must pay to fund operations or limiting the financing available to support its artificial-heart business.
If it comes in below expectations
Lower rates can make future borrowing cheaper or easier to obtain, potentially reducing Picard’s financing costs or improving access to funds for its operations and artificial-heart business.
Picard Medical, Inc. earningsThis company
Picard Medical's report will show whether SynCardia artificial-heart kit sales can grow enough to narrow the gross loss created when product and service costs exceed revenue.
Compare product and related-service revenue with the costs behind it, and read Freedom Driver rental revenue alongside its maintenance costs. Rising product revenue with costs taking a smaller share would show hospital kit sales beginning to improve gross margin. If costs still exceed revenue, or rentals continue to lose money after maintenance, each sale and rental still drains cash, leaving operating losses and financing pressure unresolved.
